-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOMARIN PHARMACEUTICAL INC - DISCONTINUES DEVELOPMENT OF BMN 349, ORAL THERAPEUTIC FOR ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) - SEC FILING

Reuters·12/22/2025 14:07:32

Please log in to view news